Literature DB >> 26283198

Lidocaine Transdermal Patch: Pharmacokinetic Modeling and In Vitro-In Vivo Correlation (IVIVC).

Phani Krishna Kondamudi1,2, Phani Prasanth Tirumalasetty3,2, Rajkumar Malayandi1,2, Srinivas Mutalik4, Raviraj Pillai5,6.   

Abstract

The present study aims to develop the correlation between in vitro and in vivo skin permeation of lidocaine in its transdermal patch. In order to minimize the run-to-run variability during in vitro skin permeation studies, release normalized cumulative percent (%Ct n) was calculated. A suitable polynomial mathematical model was used to establish a correlation between time and %Ct n. Percent in vivo absorbed was calculated by using numerical deconvolution (NDC) and non-compartmental analysis (NCA) methods. Pharmacokinetic (PK) parameters such as AUC last and C max were predicted with the established in vitro-in vivo correlation (IVIVC) models. The minimum prediction errors in NDC method for C max were found to be -30.9 and -25.4% for studies I (in vivo study in human volunteers with one batch of Lidoderm patch; internal validation) and II (in vivo study in human volunteers with another batch of Lidoderm patch; external validation), respectively, whereas minimum prediction errors in NCA method were relatively low (3.9 and 0.03% for studies I and II, respectively) compared to those in NDC method. The prediction errors for AUC last were found to be less than 2% for both methods and studies. The established method in this study could be a potential approach for predicting the bioavailability and/or bioequivalence for transdermal drug delivery systems.

Entities:  

Keywords:  IVIVC; bioequivalence; lidocaine; numerical deconvolution; transdermal

Mesh:

Substances:

Year:  2015        PMID: 26283198     DOI: 10.1208/s12249-015-0390-1

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  3 in total

1.  Drug Delivery and Transport into the Central Circulation: An Example of Zero-Order In vivo Absorption of Rotigotine from a Transdermal Patch Formulation.

Authors:  Willi Cawello; Marina Braun; Jens-Otto Andreas
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2018-08       Impact factor: 2.441

2.  A quality by design approach on polymeric nanocarrier delivery of gefitinib: formulation, in vitro, and in vivo characterization.

Authors:  Navya Sree Kola Srinivas; Ruchi Verma; Girish Pai Kulyadi; Lalit Kumar
Journal:  Int J Nanomedicine       Date:  2016-12-16

3.  A Randomized, Open-Label, Bioequivalence Study of Lidocaine Topical System 1.8% and Lidocaine Patch 5% in Healthy Subjects.

Authors:  Jeffrey Gudin; Charles Argoff; Jeffrey Fudin; Emileigh Greuber; Kip Vought; Kalpana Patel; Sri Nalamachu
Journal:  J Pain Res       Date:  2020-06-22       Impact factor: 3.133

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.